Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria

Annals of Surgical Oncology

Volumn 21, Issue 12, 2014, Pages 3835-3843

  Liu, Po Hong ^a,b   Lee, Yun Hsuan ^a,b   Hsu, Chia Yang ^a,b,c   Huang, Yi Hsiang ^a,b   Chiou, Yi You ^a,b   Lin, Han Chieh ^a,b   Huo, Teh Ia ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; DOXORUBICIN; GELFOAM; HEPATITIS B SURFACE ANTIGEN; IODINATED POPPYSEED OIL;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERFORMANCE STATUS SCALE; PROPENSITY SCORE; RADIOFREQUENCY ABLATION; RATING SCALE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPARATIVE STUDY; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84918782976     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3831-2     Document Type: Article

References (31)

1. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 10. Lyon; International Agency for Research on Cancer. 2010. http://globocan.iarc.fr. Accessed 1 May 2013.
2. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
3. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56 Suppl 1:S75–87.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.
5. Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006–14.
6. Fontana RJ, Hamidullah H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transplant. 2002;8:1165–74.
7. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.
8. Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transplant. 2014;20:528–35.
9. Bargellini I, Sacco R, Bozzi E, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–8.
10. Hsu KF, Chu CH, Chan DC, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012;81:466–71.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
12. Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17 Suppl 2:98–102.
13. Hsu CY, Lee YH, Hsia CY, et al. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol. 2013;20:2035–42.
14. Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112–9.
15. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
16. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12–25.
17. Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108–17.
18. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant. 2004;10:S115–20.
19. Lee YH, Hsu CY, Huang YH, et al. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol. 2012;27:1581–8.
20. Pearl J. Understanding propensity scores. In: Pearl J, editor. Causality: models, reasoning, and inference. 2nd ed. Cambridge: Cambridge University Press; 2009:348–51.
21. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.
22. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–61.
23. Lo CM. Deceased donation in Asia: challenges and opportunities. Liver Transplant. 2012;18 Suppl 2:S5–7.
24. Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009;115:1914–23.
25. Kong WT, Zhang WW, Qiu YD, et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol. 2009;15:2651–6.
26. Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226–33.
27. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.
28. Hsu CY, Huang YH, Chiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transplant. 2011;17:556–66.
29. Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010;25:403–7.
30. Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590–9.
31. Kalva SP, Pectasides M, Liu R, et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381–7.